IA
RUBY

IFP Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

IFP Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed -$2K – 3633
2018
Q4 		$2K Sell
100
-679
-87% -$12.4K ﹤0.01% 3223
2018
Q3 		$19K Buy
+779
New +$17.8K ﹤0.01% 2490

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

IFP Advisors's RUBY Position: Q1 2019 in Review

IFP Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2019, closing a stake of 100 shares — an estimated $2K sold.

IFP Advisors first reported a position in RUBY in Q3 2018 and held it in 2 quarters. The position peaked at $19K in Q3 2018. 67 funds tracked by Wall St. Rank hold RUBY as of Q1 2019.

  • IFP Advisors reported no remaining Rubius Therapeutics, Inc position as of Q1 2019 after selling out during the quarter.
  • IFP Advisors sold 100 Rubius Therapeutics, Inc shares in Q1 2019, an estimated $2K.
  • IFP Advisors first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 2 quarters.
  • IFP Advisors's Rubius Therapeutics, Inc position peaked at $19K in Q3 2018.
  • 67 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2019.

Based on IFP Advisors's 13F filing for Q1 2019, filed 15 May 2019.